Stocktoria
BIOVIE INC. BIVI
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-01-14
BIOVIE INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $9.3M | $23.1M | $33.3M | $17.3M | $2.5M |
| SG&A expense | $8.6M | $8.8M | $11.6M | $9.8M | $4.6M |
| Operating income | -$18.1M | -$32.2M | -$45.1M | -$27.3M | -$138.1M |
| Interest expense | — | $2.9M | $4.3M | $2.2M | $559,455 |
| Net income | -$17.5M | -$32.1M | -$50.3M | -$26.1M | -$130.2M |
| EPS (diluted) | $-12.12 | $-73.05 | $-15.47 | $-1.06 | $-14.82 |
| Operating cash flow | -$19.0M | -$27.9M | -$40.3M | -$19.0M | -$10.5M |
| Cash & equivalents | $17.5M | $23.8M | $19.5M | $18.6M | — |
| Total assets | $21.6M | $25.2M | $35.1M | $20.1M | $6.0M |
| Total liabilities | $2.6M | $9.7M | $19.8M | $16.4M | $996,374 |
| Shareholders' equity | $19.0M | $15.5M | $15.3M | $3.7M | $5.1M |
Source: SEC EDGAR filings · CIK 0001580149 · as of 2025-06-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.